Core Insights - Crystal Tech Holdings (02228.HK) announced that its incubated company, ReviR, received approval from the National Medical Products Administration for the clinical trial of RTX-117, a small molecule pipeline for treating Charcot-Marie-Tooth disease (CMT), set to begin Phase I trials in Q1 2026 [1] - RTX-117 is the first Class 1 innovative drug targeting CMT in China and represents a significant milestone in the collaboration between ReviR and Crystal Tech, leveraging AI and robotic-assisted research for rare disease drug development [1][2] - The drug has also received IND approval and orphan drug designation from the FDA, allowing for priority review and extended market exclusivity in the U.S. [1] Company and Industry Summary - CMT is listed as the 17th rare disease in the first batch published by the National Health Commission in 2018, characterized by its progressive nature and high disability rate, with RTX-117's clinical approval marking a breakthrough in CMT treatment development in China [2] - The collaboration between ReviR and Crystal Tech utilizes AI and RNA technology, demonstrating the potential of AI-driven drug discovery to overcome economic bottlenecks in rare disease treatment [2][3] - Crystal Tech, as the first "AI + Robotics" stock in Hong Kong, has established a leading automated research infrastructure and intelligent drug development platform, gaining trust from 17 of the top 20 global pharmaceutical companies [3] - The company’s platform-based business model allows for the continuous incubation of innovative pipelines, providing partners with breakthrough innovations while sharing long-term value through revenue sharing [3]

Core Viewpoint - ReviR, a company incubated by JingTai Technology, has received approval from the National Medical Products Administration (NMPA) for its small molecule pipeline RTX-117, aimed at treating Charcot-Marie-Tooth disease (CMT), with Phase I clinical trials set to begin in Q1 2026 [1] Group 1: Company Developments - RTX-117 is the first Class 1 innovative drug in China targeting CMT and is the first project to enter clinical trials from a series of rare disease drug pipelines developed through AI and robotic-assisted research [1][3] - JingTai Technology will receive milestone payments and has the right to participate in revenue sharing from sales and subsequent licensing of the RTX-117 pipeline [1] - The drug has already received IND approval and orphan drug designation from the FDA, allowing for priority review and extended market exclusivity [1] Group 2: Market Potential - CMT is listed as the 17th rare disease in the first batch of rare diseases published by the National Health Commission in 2018, with a global prevalence of 17.7 to 40 per 100,000, affecting over 2.6 million patients [2] - The global CMT treatment market is projected to grow from $1.013 billion in 2024 to $11.394 billion by 2035, reflecting a compound annual growth rate (CAGR) of 24.62% [2] - The median age of onset for CMT patients is 7.3 years, with a long diagnostic cycle and a lack of effective treatment options, indicating a significant unmet clinical need [2] Group 3: Innovation and Technology - RTX-117 targets the key physiological mechanisms causing CMT by inhibiting the Integrated Stress Response (ISR) pathway, showing significant preclinical efficacy in restoring motor function in model animals [4] - The development of RTX-117 exemplifies the potential of AI and RNA modulation in accelerating breakthroughs in rare disease therapies [3][4] - JingTai Technology's platform integrates quantum physics, AI, and large-scale robotic experimentation, establishing a leading automated drug development infrastructure [6] Group 4: Industry Challenges and Opportunities - The global rare disease market is characterized by a significant commercial opportunity, with only 5% of the over 7,000 identified rare diseases having clear treatment options [5] - Domestic rare disease patients face challenges such as high costs and low accessibility of imported drugs, highlighting the need for innovative solutions [5] - The AI-driven approach to drug development is expected to accelerate the creation of clinically valuable and marketable therapies, providing new opportunities in the rare disease treatment landscape [5]

Core Viewpoint - ReviR, a company incubated by Jingtai Technology, has received approval from the National Medical Products Administration for clinical trials of RTX-117, a small molecule drug for Charcot-Marie-Tooth disease (CMT), set to begin in Q1 2026 [2] Group 1: Company Developments - RTX-117 is the first innovative Class 1 drug targeting CMT in China and marks the first clinical project from a series of rare disease drug pipelines developed through AI and robotic-assisted research [2] - Jingtai Technology will receive milestone payments and has the right to participate in sales revenue sharing and future licensing income from the RTX-117 pipeline [2] Group 2: Industry Insights - The economic constraints of traditional drug development have long limited breakthroughs in rare disease treatments, but AI-driven precision drug discovery is changing this paradigm [2] - The clinical progress of RTX-117 validates Jingtai's platform's rapid translation capability from algorithms to clinical applications, highlighting the significant potential of the AI+RNA research path in rare disease drug development [2] - The RTX-117 pipeline has previously received IND approval and orphan drug designation from the FDA, allowing it to benefit from priority review and extended market exclusivity in overseas markets [2]